This month, we had the honor of welcoming Lehendakari Imanol Pradales and key members of his government team to our facilities; Mikel Jauregi, Minister of Industry, Energy Transition and Sustainability; Juan Ignacio Pérez Iglesias, Minister of Science, University, and Innovation; and Jaione Ganzarain, Deputy Minister of Technology, Innovation, and Digital Transformation.
During their visit, we had the opportunity to share Viralgen’s mission of bringing advanced treatments to those who need them most, to showcase the science that takes place in our laboratories and give insights on AAVs (Adeno-Associated Virus vectors) manufacturing process, critical to gene therapies.
We are deeply grateful to have hosted these important visitors/ stakeholders and appreciate the continuous support critical for developing innovative therapies in the Basque country. This visit strengthens our commitment to health and innovation, as we work together to advance progress in the field of gene therapies.
Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.
Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.